Table 6 Dose escalation trials for stereotactic body radiotherapy for prostate cancer patients
Author | Year | n | Dose and fractionation | Follow-up | Biochemical control | Acute GU | Acute GI | Lage GU | Late GI |
|---|---|---|---|---|---|---|---|---|---|
Zelefsky | 2019 | 136 | 32.5Gy - 40Gy in 5fx | 3.5–5.9 years | 5 years: 85–100% | G2: 8.3–22.9% ≥G3: 0% | G2: 0–11.4% ≥G3: 0% | G2: 23.3–31.4% ≥G3: 0–2.9% | G2: 0% ≥G3: 0% |
Hannan | 2016 | 91 | 45Gy–50Gy in 5fx | 66–74 months | 5 years: 90.9–100% | G2: 6.7–33.3% ≥G3: 0% | G2: 6.7–26.7% ≥G3: 0–3.2% | G2: 19.7–26.7% ≥G3: 0–6.7% | G2: 0–18% ≥G3: 0–9.9% |
McBride | 2012 | 45 | 36.25Gy–37.5Gy in 5fx | 44.5 months | 3 years: 100% | G2: 19% ≥G3: 0% | G2: 7% ≥G3: 0% | G2: 17% ≥G3: 2% | G2: 7% ≥G3: 5% |
Present study | 27 | 32Gy–36Gy in 4fx | 42 months | 3 years: 90.3% | G2: 0–33% ≥G3: 0% | G2: 0–11% ≥G3: 0% | G2: 0–11% ≥G3: 0% | G2: 0–11% ≥G3: 0% | |